



REPUBLIC OF KOSOVA

KEKA Amir (amir.keka@rks-gov.net)

DOCI Njomza (njomza.doci@rks-gov.net) REXHEPI Teuta (teuta.m.rexhepi@rks-gov.net)

Health Insurance Fund



PPRI

Pharmaceutical Pricing and Reimbursement Information



Population – 1.773,971M,
Health expenditure: 6%

Recent and planned developments in pharmaceutical policies 2025

Pricing of medicines

price regulation has been implementing since February 2025

The Law on Medicinal Product Pricing has been approved in 2023. The competent authorities / decision making institutions for **pricing of medicines** is Ministry of Health.

This law shall apply to retail and wholesale distributors of medicinal products, the representative of the marketing authorization holder, the marketing authorization holder and public institutions.

Reference Countries: primary: Albania, Montenegro, North Macedonia, Croatia and the country of origin. secondary: Slovenia, Estonia, Bulgaria and the country of origin.

Calculate method: The price of the medicinal product is determined by calculating the average wholesale price of the two lowest prices of that product from the reference countries.

Type of comparator price – Wholesale price and CIP import prices
Source of Pricing Information – Public official sources; Market Authorization Holders.

Price revisions frequency – regular price review annually or as required in cases of significant price changes.

Coverage Reimbursement

The Law on Health Insurance was approved by the Parliament in December 2024, and expected to be fully implemented in coming years

The competent authorities /decision making institutions for **coverage /reimbursement of** medicines are Ministry of Health and Health Insurance Fund.

The National Essential Medicine List (NEML) was updated during 2024 by Key Committee for Compiling the NEML. All the medicines from NEML are covered by public funds and there is no co-payment by patients (In-patient sector).

Upcoming: Out – Patient sector

Reimbursement policy will be determined by the government's decision on which drugs will be covered, the available budget and how much HIF covers.

The benefit will cover a very limited list of drugs that will be prescribed by the family medicine centre and will be provided free of charge in contracted private pharmacies.

The expansion of drugs will continue as revenues increase. There is no reimbursement for drugs that are not part of the reimbursement list

HTA

Kosova doesn't have a fully established national HTA agency

Total expenditure in the health sector: 576M €

Public spending, including donations: 305.4M € - Private spending: 242.1M €, Private insurance spending: 28.3M; OOP: 197.17M €

OOP expenses account 40% of the total health expenses, of which 80% are only for medicines the total expenditure on drugs amounts to 173.5M, 29% of which is covered by the state while 71% remains OOP.